Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer
Retrieved on:
星期四, 十月 19, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Hyperoxaluria, Heidelberg University School of Medicine, Proctor, Endocrinology, Nephrology, Publication, Inflammation, Metabolism, Corcept Therapeutics, Baylor College of Medicine, Medicine, Amgen, Internal medicine, Neurology, Corporation, University, NDA, Safety, Therapy, Patient, BLA, Baylor University, Pharmaceutical industry, Management, Omeros
Omeros Corporation (Nasdaq: OMER) today announced that Andreas Grauer, M.D., has been named Omeros’ chief medical officer.
Key Points:
- Omeros Corporation (Nasdaq: OMER) today announced that Andreas Grauer, M.D., has been named Omeros’ chief medical officer.
- In his new role, Dr. Grauer will be responsible for guiding all clinical activities globally for the company, including clinical development and operations, medical affairs, safety, and biometrics.
- “We are very pleased to welcome Andreas to Omeros’ leadership team,” said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros.
- He joins Omeros from Federation Bio where, as chief medical officer, he led all clinical activities with a focus on hyperoxaluria and immuno-oncology.